Nuvectis Pharma (NVCT) vs Silence Therapeutics Plc American Depository Share (SLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nuvectis Pharma (NVCT) has outperformed Silence Therapeutics Plc American Depository Share (SLN) over the past year, gaining 223.1% versus a gain of 81.3%. Nuvectis Pharma is the larger company by market cap ($660.4 million vs $639.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVCT | SLN |
|---|---|---|
| Share price | $20.23 | $10.29 |
| Market cap | $660.39M | $639.57M |
| 1-day change | +0.50% | +8.09% |
| YTD return | +166.62% | +56.58% |
| 1-year return | +223.11% | +81.33% |
| 5-year return | — | -56.37% |
| EPS (TTM) | $-1.31 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $29.28 | $17.58 |
| 52-week low | $5.55 | $4.19 |
| Distance from 52-week high | -30.90% | -41.45% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +74.99% | +220.70% |
| Average volume | 215.43K | 1.14M |
| Shares outstanding | 32.64M | 62.15M |
| Employees | 16 | 88 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCT has outperformed SLN by 141.8 percentage points over the past year.
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About Silence Therapeutics Plc American Depository Share
SLN stock →Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
NVCT vs SLN FAQ
Which is bigger, Nuvectis Pharma or Silence Therapeutics Plc American Depository Share?
Nuvectis Pharma (NVCT) is larger, with a market capitalization of $660.39M compared with $639.57M for Silence Therapeutics Plc American Depository Share (SLN).
Which stock has performed better over the past year, NVCT or SLN?
NVCT returned +223.11% over the past 12 months, compared with +81.33% for SLN (price return, excluding dividends). Past performance does not predict future results.
Are Nuvectis Pharma and Silence Therapeutics Plc American Depository Share in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.